MILAE BIORESOURCES CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,390 KRW | -0.74% |
|
+3.06% | +23.91% |
| 2021 | Milae Bioresources Co., Ltd. announced that it has received KRW 15 billion in funding | CI |
| 2021 | Milae Bioresources Co., Ltd. announced that it expects to receive KRW 15 billion in funding | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 56,294 | 51,403 | 53,257 | 70,503 | 73,056 | 84,806 |
| Enterprise Value (EV) 1 | 49,119 | 41,510 | 45,021 | 60,163 | 56,970 | 63,270 |
| P/E ratio | 29.6 x | 49.9 x | 56.1 x | 62.1 x | 75.5 x | 190 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.6 x | 1.03 x | 1.12 x | 1.06 x | 0.97 x | 1.41 x |
| EV / Revenue | 1.4 x | 0.83 x | 0.95 x | 0.9 x | 0.75 x | 1.05 x |
| EV / EBITDA | 21.7 x | 20.5 x | 24 x | 21.7 x | 21.8 x | 58.8 x |
| EV / FCF | -6.94 x | 14.5 x | 66.2 x | 54.8 x | -89.5 x | 34.4 x |
| FCF Yield | -14.4% | 6.91% | 1.51% | 1.82% | -1.12% | 2.91% |
| Price to Book | 1.89 x | 1.73 x | 1.75 x | 2.14 x | 1.79 x | 1.92 x |
| Nbr of stocks (in thousands) | 18,671 | 17,786 | 17,693 | 17,737 | 18,976 | 19,496 |
| Reference price 2 | 3,015 | 2,890 | 3,010 | 3,975 | 3,850 | 4,350 |
| Announcement Date | 3/14/19 | 3/19/20 | 3/23/21 | 3/21/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 35,199 | 50,079 | 47,497 | 66,668 | 75,635 | 60,016 |
| EBITDA 1 | 2,264 | 2,023 | 1,880 | 2,776 | 2,612 | 1,076 |
| EBIT 1 | 1,981 | 1,365 | 1,159 | 1,855 | 1,583 | 20.19 |
| Operating Margin | 5.63% | 2.73% | 2.44% | 2.78% | 2.09% | 0.03% |
| Earnings before Tax (EBT) 1 | 1,891 | 1,250 | 1,034 | 1,144 | 905.4 | 392.9 |
| Net income 1 | 1,776 | 1,030 | 951.8 | 1,143 | 962.8 | 441.3 |
| Net margin | 5.05% | 2.06% | 2% | 1.71% | 1.27% | 0.74% |
| EPS 2 | 102.0 | 57.90 | 53.68 | 64.00 | 51.00 | 22.94 |
| Free Cash Flow 1 | -7,073 | 2,866 | 679.9 | 1,097 | -636.9 | 1,839 |
| FCF margin | -20.09% | 5.72% | 1.43% | 1.65% | -0.84% | 3.06% |
| FCF Conversion (EBITDA) | - | 141.73% | 36.17% | 39.53% | - | 170.94% |
| FCF Conversion (Net income) | - | 278.36% | 71.43% | 96.03% | - | 416.68% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/14/19 | 3/19/20 | 3/23/21 | 3/21/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 7,175 | 9,893 | 8,235 | 10,341 | 16,086 | 21,535 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -7,073 | 2,866 | 680 | 1,097 | -637 | 1,839 |
| ROE (net income / shareholders' equity) | 6.69% | 3.55% | 3.16% | 3.39% | 2.38% | 0.85% |
| ROA (Net income/ Total Assets) | 3.81% | 2.35% | 1.87% | 2.45% | 1.77% | 0.02% |
| Assets 1 | 46,661 | 43,821 | 50,957 | 46,548 | 54,253 | 1,886,093 |
| Book Value Per Share 2 | 1,598 | 1,668 | 1,721 | 1,854 | 2,147 | 2,265 |
| Cash Flow per Share 2 | 117.0 | 251.0 | 159.0 | 1,023 | 398.0 | 102.0 |
| Capex 1 | 5,667 | 450 | 216 | 530 | 486 | 627 |
| Capex / Sales | 16.1% | 0.9% | 0.45% | 0.8% | 0.64% | 1.04% |
| Announcement Date | 3/14/19 | 3/19/20 | 3/23/21 | 3/21/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +23.91% | 77.83M | |
| +18.35% | 12.15B | |
| +13.73% | 6.57B | |
| +2.99% | 5.36B | |
| +14.80% | 5.09B | |
| -17.79% | 2.79B | |
| +4.52% | 1.95B | |
| -5.87% | 1.37B | |
| -7.83% | 975M | |
| -14.94% | 966M |
- Stock Market
- Equities
- A218150 Stock
- Financials Milae Bioresources Co., Ltd.